Mounjaro is not cheap. It is a new biologic medication, currently without a generic version, and the global pricing reflects that. South African pricing, set within the SEP (single exit price) framework, is broadly aligned with the Aspen distribution model.

Here is the honest picture.

Pricing Structure

Mounjaro is sold in single dose pre-filled KwikPens. Each pen is one weekly injection. A month of treatment is four pens.

SA pricing at launch (early 2025):

  • 2.5 mg and 5 mg pens: approximately R880 per pen
  • 7.5 mg and 10 mg pens: approximately R1140 per pen
  • 12.5 mg and 15 mg pens: higher again at typical SEP increments

This means a month of treatment typically ranges from around R3500 at the lower doses to over R5000 at higher doses, depending on the pharmacy and current SEP. Pharmacy dispensing fees may add to this.

Always confirm with your pharmacy Prices change with SEP updates and stock availability. Confirm the current cost at the pharmacy you plan to use before booking a consultation. Online Doctor SA's consultation fee is separate.

How Cost Scales With Dose

The titration means costs are lower in the early months. A typical pattern:

  • Month 1: 2.5 mg weekly. Lowest cost month.
  • Month 2: 5 mg weekly.
  • Month 3: 7.5 mg weekly.
  • Month 4: 10 mg weekly. Many people stop here as a therapeutic dose.
  • Beyond: 12.5 mg or 15 mg if needed.

People who respond well at lower doses and do not need to escalate keep ongoing costs lower. People who need the higher doses pay more per month.

Medical Aid Coverage

This is where SA pricing gets nuanced. Coverage varies considerably.

For type 2 diabetes

Several SA medical aids include tirzepatide on formularies for type 2 diabetes treatment, particularly on higher options. PMB (Prescribed Minimum Benefit) cover for diabetes can apply. The specifics depend on scheme and plan.

For weight management

Cover is more variable. Some plans cover GLP-1 medications for obesity, with criteria around BMI, comorbidities, and use of structured weight management programmes. Many plans do not cover weight management medications at all, treating them as 'lifestyle' rather than treatment for a medical condition.

The October 2025 SAHPRA approval for weight management may shift this over time as more schemes update their formularies, but at the time of writing many people pay for weight management Mounjaro out of pocket.

Practical step

Call your medical aid directly, quoting the medication name (Mounjaro / tirzepatide) and the intended use (diabetes or chronic weight management). Ask whether it is on formulary, what the criteria are, and whether prior authorisation is needed.

Get An Assessment To Discuss Cost

The consulting doctor can help you understand what dose you are likely to settle on, which affects ongoing cost.

Start Consultation

How To Reduce Ongoing Cost

Confirm pharmacy pricing

Pricing varies between major retail pharmacies, independent pharmacies, and online dispensing pharmacies. Compare before settling on a regular supplier.

Stay at the lowest effective dose

Higher doses cost more. Many people respond well at 5 mg or 10 mg. There is no benefit in going to 15 mg if a lower dose is producing what you and your doctor have agreed is the right outcome.

Medical aid optimisation

Some plans cover the medication at certain levels but require chronic disease registration or particular paperwork. The consulting doctor can usually provide the supporting documentation.

Tax claim

Medical expenses, including out of pocket prescription medications, may be claimable depending on your tax situation. Keep your invoices.

What To Be Careful Of

Avoid unregulated 'cheap' alternatives There are websites and online sellers offering 'tirzepatide' outside the regulated pharmacy chain, often as 'compounded' versions or 'research peptides'. These are unregulated, often substandard, and sometimes falsified entirely. SAHPRA has issued specific warnings. The Aspen distributed Mounjaro from a SAPC registered pharmacy is the only safe route.

Future Pricing

Two factors will likely reduce cost over time. First, supply scaling and competition from other dual incretin medications (several are in late stage development). Second, eventual patent expiry, opening the way for generic competition. Neither is imminent. For the foreseeable future, Mounjaro pricing in SA is what it is.

Is It Worth The Cost

That is a personal calculation the consulting doctor and the person need to work through. Considerations:

  • What conditions is the medication treating
  • What benefit is realistic given your specific situation
  • What is the cost of not treating (in long term medical costs, quality of life, productivity)
  • What other treatment options are available at what cost and effectiveness

The medication is not a luxury purchase. It is treatment for serious chronic conditions. For people who meet the eligibility criteria and respond well, the health benefit is substantial. For people who would respond as well to cheaper interventions, it may not be the right choice.

Related Reading

Frequently Asked

It is a new patented biologic medication, costly to manufacture, and currently has no generic version. Once the patent expires in years to come, prices will drop, but for now there is no generic alternative.

Some plans cover Mounjaro for type 2 diabetes. Cover for weight management is more variable and depends on the scheme and option. Check with your medical aid directly.

For weight management, older medications like liraglutide (Saxenda) or orlistat (Xenical) are options at lower cost but with smaller average effect. For diabetes, older medications like metformin and SGLT2 inhibitors are much cheaper and remain first or second line for many people.

Importing prescription medication for personal use is restricted in South Africa, and overseas suppliers selling tirzepatide outside the regulated pharmacy chain are often unreliable. SAHPRA has warned about substandard and falsified GLP-1 products. The locally distributed Aspen version is the regulated route.